Zoetis Q2FY26 Results: Organic revenue falls 1%, full-year outlook cut
- Organic revenue declined 1% to $2.5 billion, with adjusted net income down 2% to $781 million
- US Companion Animal revenue fell 11%, driven by lower clinic visits and intense competition in dermatology and parasiticides
- Livestock segment grew 11% globally, with US Livestock surging 23% due to screwworm-related demand and cattle strength
- Full-year organic revenue guidance revised to a decline of 3% to 1%, reflecting persistent market pressures
- Leadership reshuffle announced with Jay Zakara joining as CFO and COO to drive operational efficiency
*this image is generated using AI for illustrative purposes only.
Zoetis Inc reported a 1% decline in organic operational revenue for the second quarter of fiscal year 2026, as competitive pressures and softer demand in the US companion animal sector outweighed strong livestock performance.
Global revenue stood at $2.5 billion, flat on a reported basis. Adjusted net income fell 2% organically to $781 million. The company revised its full-year guidance, now expecting organic revenue to decline between 3% and 1%, with adjusted net income falling 9% to 5%.
Segment performance divergence
The quarter highlighted a stark contrast between the struggling US companion animal business and the robust livestock segment. US revenue dropped 7% to $1.3 billion, driven by an 11% decline in US Companion Animal sales. In contrast, international revenue rose 6% to $1.2 billion, supported by emerging markets.
The Livestock segment delivered strong growth of 11% globally, reaching $731 million. This was led by a 23% surge in US Livestock revenue, attributed to increased demand for parasiticides following New World screwworm incursions and favorable producer economics in cattle and poultry.
| Segment | Revenue | YoY Change (Organic) | Key Driver |
|---|---|---|---|
| Global Total | $2.5 billion | -1% | Mixed portfolio performance |
| US Companion Animal | $1.0 billion | -11% | Lower clinic visits, competition |
| International | $1.2 billion | +6% | Emerging market strength |
| Livestock | $731 million | +11% | Cattle, poultry, screwworm demand |
| Diagnostics | $118 million | +12% | Urgent care adoption |
Companion animal headwinds
The companion animal portfolio faced significant pressure, with global revenue declining 6%. Dermatology, a key franchise, saw revenue drop 16% globally to $395 million, with US dermatology falling 18%. The company cited increased competitive intensity, including new entrants using aggressive discounting and rebates, alongside a multi-year trend of declining veterinary clinic visits.
In parasiticides, the Simparica franchise remained flat globally at $442 million. While international growth was strong, particularly for Simparica Trio, US performance declined 6% due to softer wellness visits and generic competition affecting products like Cerenia and Convenia.
Leadership changes and strategic response
Zoetis announced significant leadership updates to address these challenges. Jay Zakara will join as EVP, Chief Financial Officer, and Chief Operating Officer, a newly created role overseeing finance, manufacturing, and supply. Abhay Nayak has been promoted to EVP and president of US commercial operations. These moves aim to accelerate decision-making and strengthen commercial execution.
The company is deploying targeted gross-to-net investments, including promotions and rebates, to defend market share without permanently lowering list prices. This strategy contributed to the flat price realization in the quarter but is expected to impact full-year margins.
What the numbers show
A key analytical observation from the filing is the resilience of the Livestock segment against the contraction in Companion Animal. While US Companion Animal revenue fell 11%, US Livestock grew 23%. This suggests that while pet owners are becoming more value-conscious and reducing discretionary veterinary spending, agricultural producers are maintaining or increasing investment in animal health, driven by distinct economic factors such as protein demand and disease management needs. The company’s reliance on this counter-cyclical strength is critical to offsetting the broader consumer-driven slowdown in its core pet health business.
How will the newly created combined CFO/COO role under Jay Zakara specifically alter Zoetis' supply chain efficiency and capital allocation strategies in the coming quarters?
To what extent is the surge in US Livestock revenue driven by temporary factors like the New World screwworm incursion versus sustainable structural demand in the agricultural sector?
What are the projected long-term margin impacts if Zoetis continues to rely on gross-to-net investments and rebates to defend market share against aggressive competitor discounting?
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
